SeaCrest Wealth Management’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

SeaCrest Wealth Management’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-70	Closed	-$2K	–	1983
2019 Q1	$2K	Hold	70	–	–	﹤0.01%	1965
2018 Q4	$2K	Buy	70 +25	+56%	+$1.11K	﹤0.01%	1947
2018 Q3	$3K	Hold	45	–	–	﹤0.01%	2012
2018 Q2	$3K	Hold	45	–	–	﹤0.01%	1957
2018 Q1	$3K	Sell	45 -60	-57%	-$4.53K	﹤0.01%	1936
2017 Q4	$9K	Buy	+105	New	+$10.3K	﹤0.01%	1648

Other funds holding BLCM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

SeaCrest Wealth Management's BLCM Position: Q2 2019 in Review

SeaCrest Wealth Management sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q2 2019, closing a stake of 70 shares — an estimated $2K sold.

SeaCrest Wealth Management first reported a position in BLCM in Q4 2017 and held it in 6 quarters. The position peaked at $9K in Q4 2017. 79 funds tracked by Wall St. Rank hold BLCM as of Q2 2019.

SeaCrest Wealth Management reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
SeaCrest Wealth Management sold 70 Bellicum Pharmaceuticals, Inc. shares in Q2 2019, an estimated $2K.
SeaCrest Wealth Management first reported a position in Bellicum Pharmaceuticals, Inc. in Q4 2017 and held it in 6 quarters.
SeaCrest Wealth Management's Bellicum Pharmaceuticals, Inc. position peaked at $9K in Q4 2017.
79 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q2 2019.

Based on SeaCrest Wealth Management's 13F filing for Q2 2019, filed 19 Jul 2019.